Results 251 to 260 of about 111,074 (325)
Detection of Anaphylaxis Through the Cutaneous Barrier. [PDF]
Sundar A, McMorris MS, Schuler CF.
europepmc +1 more source
ABSTRACT Background Identification of offending foods in dogs with adverse food reactions is usually based on “deterioration” during open food challenges. Objectives To examine the placebo effect during double‐blinded, placebo‐controlled food challenges using a predefined set of criteria for relapse.
Evi I. Sofou +4 more
wiley +1 more source
Anaphylaxis to dextromethorphan with positive skin testing: a case report. [PDF]
Badawod E, Campbell J, Lee E.
europepmc +1 more source
Clinical manifestations of Florida spot keratopathy in dogs and cats: One hundred cases (2021–2024)
Abstract Purpose This study describes the ocular findings in dogs and cats diagnosed with Florida spot keratopathy (FSK) at a single institution. Methods Affected animals underwent a single comprehensive ophthalmic examination, with no follow‐ups conducted. Data on patient demographics and clinical findings were collected and analyzed. Results Based on
O. Pe'er +4 more
wiley +1 more source
Anaphylaxis secondary to ingestion of pumpkin seeds in a child: A case report
SarahF Alsukait, AbdullahA Alangari
openalex +1 more source
Anaphylaxis and Advances in Anaphylaxis
Mahmut Dogru, Ilknur Bostanci
openaire +1 more source
Assessment of allergy knowledge among the Palestinian community: A cross-sectional study. [PDF]
Rabayaa M +7 more
europepmc +1 more source
Abstract Secondary aortoduodenal fistula (sADF) is a rare but life‐threatening complication after aortic graft surgery. Diagnosis is often challenging, particularly when contrast‐enhanced computed tomography (CT) and endoscopy results are inconclusive. We report a case in which diagnosis was challenging due to contrast media allergy and non‐diagnostic ...
Jun Kubota +6 more
wiley +1 more source
Emergency management of anaphylaxis and the impact of the new UK advanced life support guidelines. [PDF]
Elshehawy M +8 more
europepmc +1 more source
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa +2 more
wiley +1 more source

